<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1078">
  <stage>Registered</stage>
  <submitdate>21/02/2006</submitdate>
  <approvaldate>21/02/2006</approvaldate>
  <nctid>NCT00295165</nctid>
  <trial_identification>
    <studytitle>Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease</studytitle>
    <scientifictitle>Randomized, Double-Blind, Placebo-Controlled, Phase 3 Induction Study to Assess the Efficacy and Safety of 6µg Sargramostim (Leukine) Administered Subcutaneously Once Daily for 8 Weeks in Patients With Active Crohn's Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>91494</secondaryid>
    <secondaryid>310187</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Crohn Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Crohn's disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Sargramostim (Leukine)
Treatment: drugs - Placebo

Experimental: Arm 1 - 

Placebo Comparator: Arm 2 - 


Treatment: drugs: Sargramostim (Leukine)
Sargramostim 6 mcg/kg subcutaneously once daily

Treatment: drugs: Placebo
Placebo subcutaneously once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To induce clinical remission and/or clinical response following 8 weeks of treatment</outcome>
      <timepoint>8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the safety profile of sargramostim (including development of antibodies against sargramostim)</outcome>
      <timepoint>During study treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess quality of life (QoL)</outcome>
      <timepoint>During study treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Written informed consent

          2. Male or female, age &gt;/= 18 years

          3. Confirmed diagnosis of Crohn's disease (endoscopic or radiological evaluation) at
             least 4 months prior to receiving the first dose of study drug

          4. Moderately to severely active Crohn's disease at time of screening (i.e., CDAI greater
             than or equal to 220 and less than or equal to 475 points)

          5. If under treatment for Crohn's disease, medication must be stable for at least 4 weeks
             prior to receiving the first dose of study drug. The following therapies are allowed:

               -  Oral therapy with salicylates (mesalamine, sulfasalazine, olsalazine, or
                  balsalazide) for Crohn's disease

               -  Antibiotics or probiotics for Crohn's disease

               -  Topical rectal therapy with mesalamine

          6. Females of child-bearing potential:

             Negative pregnancy test within 72 hours prior to receiving the first dose of study
             drug

          7. Sexually-active males and females of child-bearing potential:

             Agreement to use adequate method of contraception throughout the study

          8. Ability to self-inject study drug or availability of a designee who can do so</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Pregnancy or breast-feeding

          2. Colostomy or ileostomy

          3. Immediate need for gastrointestinal (GI) surgery for active GI bleeding, peritonitis,
             intestinal obstruction, or intra-abdominal or perianal abscess requiring surgical
             drainage

          4. GI surgery within 6 months prior to receiving the first dose of study drug

          5. Symptoms of bowel obstruction or confirmed evidence of a clinically-significant
             stricture within the last 6 months that has not been surgically corrected

          6. Positive stool test results for any of the following:

             Bacteria:

               -  Salmonella spec.

               -  Shigella spec.

               -  Campylobacter spec.

             Bacterial toxin:

               -  Clostridium difficile

             Ova and parasites:

               -  Amoeba spec.

               -  Giardia spec.

               -  Cryptosporidium spec.

          7. Any of the following laboratory abnormalities:

               -  Serum creatinine &gt;/= 2.0 mg/dL

               -  Alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine
                  aminotransferase (ALT), or total bilirubin &gt;/=; 2 x the upper limit of normal

               -  Hemoglobin (Hgb) &lt; 8.0 g/dL

               -  Absolute neutrophil count (ANC) &lt;/= 1,000 cells/µL or &gt; cells 20,000/µL

          8. Planned in-patient hospitalization during the study

          9. Presence or history of cancer of any type (except treated basal cell carcinoma) or
             definite dysplasia of the colon within the last 5 years

         10. Use of any of the following medications during the specified period of time prior to
             receiving the first dose of study drug:

             At any time:

               -  Recombinant human GM CSF (sargramostim or molgramostim)

               -  Granulocyte colony-stimulating factor (G CSF; filgrastim or pegfilgrastim)

               -  Natalizumab 8 weeks: or 5 half-lives (whichever is longer)

               -  Licensed/registered and/or experimental anti-tumor necrosis factor (TNF) therapy
                  such as infliximab or adalimumab 4 weeks:

               -  6-mercaptopurine

               -  Azathioprine

               -  Cyclophosphamide

               -  Methotrexate

               -  Mycophenolate mofetil

               -  Tacrolimus

               -  Cyclosporine

               -  Thalidomide

               -  Glucocorticoids, including budesonide and prednisone, or local glucocorticoid
                  therapy for Crohn's disease

               -  Any other immunosuppressive drugs

         11. Use of any investigational drug within 4 weeks or 5 half-lives (whichever is longer)
             prior to receiving the first dose of study drug

         12. Use of nutritional therapy (parenteral nutrition or enteral nutrition with elemental
             or semi-elemental diets) within 4 weeks prior to receiving the first dose of study
             drug. If the physician judges that nutritional supplementation is needed, enteral
             nutritional supplements will be allowed for patients who have been receiving a stable
             regimen for at least 4 weeks prior to receiving the first dose of study drug and that
             is intended to continue through the 8 week treatment period.

         13. History of allergy to yeast products or to sargramostim or to any other excipient of
             the study drug formulation

         14. Active drug or alcohol abuse

         15. Clinically important co-morbid conditions unrelated to Crohn's disease as determined
             by the investigator

         16. Previous randomization into this study, or into any other study of the sponsor's
             sargramostim development program</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>33</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital> - Liverpool</hospital>
    <hospital> - Caboolture</hospital>
    <hospital> - Adelaide</hospital>
    <hospital> - Frankston</hospital>
    <hospital> - Melbourne</hospital>
    <hospital> - Brisbane</hospital>
    <hospital> - Hamilton</hospital>
    <hospital> - Sydney</hospital>
    <postcode>2170 - Liverpool</postcode>
    <postcode> - Caboolture</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>3084 - Melbourne</postcode>
    <postcode>QLD 4000 - Brisbane</postcode>
    <postcode>3204 - Hamilton</postcode>
    <postcode> - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Santa Catarina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Santos</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Varna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newfoundland and Labrador</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Rehovot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Zerifin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Craiova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Krasnodar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moskva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Sankt-Peterburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Eastern Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Western Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Durban</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dnepropetrovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Ivano-Frankovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Lviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Zaporozhye</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genzyme, a Sanofi Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate if Leukine can induce clinical response or remission
      in patients with Crohn's disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00295165</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Monitor</name>
      <address>Genzyme, a Sanofi Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>